The UK and US have hammered out a landmark bilateral deal that will preserve zero levies on British medicine shipments being sold in the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise funding on medicines through the NHS. This move ensures that import taxes on these vital exports will stay at nothing for a period of the next three years.
This agreement follows earlier warnings to significantly raise tariffs on branded drug products, with increases floated up to double the cost.
"This arrangement between the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed equity to U.S.–U.K. drug exports," a release noted.
Economic Impact
Drugs are one of the Britain's largest goods shipped to the United States, which is easily the primary buyer for leading UK drugmakers.
Statistics indicate that in the year leading up to last September, the UK sold medicines totaling billions to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This deal secures employment, stimulates funding and paves the way for the UK to establish itself as a worldwide center for biotech and pharma," a minister remarked.
Specific UK Commitments
The pact includes several key pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new treatments to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates were more than 20%.
Industry Background
This agreement follows a protracted tension between the sector and the British authorities over spending levels and approval rates.
The disagreement were heightened by assertions that American patients were charged a premium for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several significant manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar investments have been pledged toward US facilities.
The Science Minister acknowledged that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
